

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No.

01579-1155

Applicant

KOEBERL et al

Filing Date


January 21, 2004

Serial No.

10/761,530

TC/A.U.

1652



U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

***Examiner**

/Ganapathiram Raghu/

Date Considered

05/13/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

Atty. Docket No.

Serial No.

01579-1155**10/761,530**

Applicant

KOEBERL et al

Filing Date

TC/A.U.

January 21, 2004**1652**
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/GR/	Sun et al, "Enhanced Efficacy of an AAV Vector Encoding Chimeric, Highly Secreted Acid α -Glucosidase in Glycogen Storage Disease Type II", Molecular Therapy 14(6):822-830 (2006)
	GenBank Accession No. NM_000477
	Xia et al, "The HIV Tat protein transduction domain improves the biodistribution of β -glucuronidase expressed from recombinant viral vectors", Nature Biotechnology 19:640-644 (2001)
	Orii et al, "Defining the Pathway for Tat-mediated Delivery of β -Glucuronidase in Cultured Cells and MPS VII Mice", Molecular Therapy 12(2):345-352 (2005)
	Poenaru, L., Approach to Gene Therapy of Glycogenosis Type II (Pompe Disease), Molecular Genetics and Metabolism, 70 (3):163-169 (2000)
	Hirschhorn, R., "Glycogen Storage Disease Type II: Acid α -Glucosidase (Acid Maltase) Deficiency", The Metabolic and Molecular Bases of Inherited Disease, (77) 11:2443-2464 (1995)
	Barton, N.W., et al., "Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease", Proc. Natl. Acad. Sci, 87:1913-1916 (Mar. 1990)
	Lauer, R.M., "Administration of a Mixture of Fungal Glucosidases to a Patient with Type II Glycogenosis (Pompe's Disease)", Pediatrics, 42:672-676 (1968)
	Van den Hout, et al., "Enzyme therapy for Pompe disease with recombinant human α -glucosidase from rabbit milk", J. Inherit. Metab. Dis., 24:266-274 (2001)
	Williams, J.C., et al., "Enzyme Replacement in Pompe Disease With an α -Glucosidase-Low Density Lipoprotein Complex", Birth Defects: Original Article Series, 16 (1):415-423 (1980)
	Yang, H.W., et al., "Recombinant Human Acid α -Glucosidase Corrects Acid α -Glucosidase-Deficient Human Fibroblasts, Quail Fibroblasts, and Quail Myoblasts", Pediatric Research, 43 (3):374-380 (1998)
	Amalfitano, A., et al., "Recombinant human acid α -glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial", Genetics in Medicine, 3 (2):132-138 (2001)
	Ausems, M., et al., "Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling", European Journal of Human Genetics, 7:713-716 (1999)
	Bijvoet, A.G.A., et al., "Recombinant human acid α -glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice", Human Molecular Genetics, 7 (11):1815-1824 (1998)
	Bijvoet, A.G.A., et al., "Human acid α -glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II", Human Molecular Genetics, 8 (12):2145-2153 (1999)
	Brooks, D.A., "Immune Response to Enzyme Replacement Therapy in Lysosomal Storage Disorder Patients and Animal Models", Molecular Genetics and Metabolism, 68:268-275 (1999)
	de Barys, T., et al., "Enzyme Replacement in Pompe Disease: An Attempt with Purified Human Acid α -Glucosidase", Birth Defects:Original Article Series, 9 (2):184-190 (1973)
	Fuller, M., et al., "Isolation and characterisation of a recombinant, precursor form of lysosomal acid α -glucosidase", Eur. J. Biochem, 234:903-909 (1995)
	Hermans, M.M.P., et al., "The effect of a single base pair deletion (Δ DELTA.T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal α -glucosidase in patients with glycogen storage disease type II", Human Molecular Genetics, 3 (12):2213-2218 (1994)
↓	Hermans, M.M.P., et al., "The conservative substitution Asp-645.fwdarw.Glu in lysosomal α -glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II", Biochem. J., 289:687-693 (1993)
/GR/	Hermans, M.M.P., et al., "Identification of a Point Mutation in the Human Lysosomal α -Glucosidase Gene Causing Infantile Glycogenosis Type II", Biochemical and Biophysical Research Communications, 179 (2):919-926 (1991)

*Examiner

/Ganapathiram Raghu/

Date Considered

05/13/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No.

Serial No.

01579-1155

10/761,530

Applicant

KOEBERL et al

Filing Date

TC/A.U.

January 21, 2004

1652

[illegible]

***Examiner**

/Ganapathiram Raghu/

Date Considered

05/13/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

Att # Pocket No.

Serial No.

09579-1155

10/761,530

KOEBERL et al

Filing Date

TC/A.U.

January 21, 2004

1652

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

A graph on lined paper showing a linear relationship. The x-axis is labeled "Time (hours)" and the y-axis is labeled "Distance (miles)". A line starts at the origin (0,0) and passes through the point (4, 100).

***Examiner**

/Ganapathiram Raghu/

Date Considered

05/13/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.